Ironwood Pharmaceuticals (IRWD) vs Tilray Brands (TLRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ironwood Pharmaceuticals (IRWD) has outperformed Tilray Brands (TLRY) over the past year, gaining 144.9% versus a loss of 79.1%. Over five years, IRWD leads with a -71.7% price change compared with -96.5% for TLRY. Ironwood Pharmaceuticals is the larger company by market cap ($639.5 million vs $520.2 million), about 1.2 times the size.
On valuation, Ironwood Pharmaceuticals trades at a lower forward P/E (2.6x vs 19.8x for Tilray Brands).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRWD | TLRY |
|---|---|---|
| Share price | $3.87 | $3.52 |
| Market cap | $639.48M | $520.19M |
| 1-day change | 0.00% | -1.95% |
| YTD return | +14.84% | -60.24% |
| 1-year return | +144.94% | -79.13% |
| 5-year return | -71.67% | -96.49% |
| P/E ratio (TTM) | 5.03 | — |
| Forward P/E | 2.58 | 19.83 |
| EPS (TTM) | $0.77 | $-1.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.78 | $20.20 |
| 52-week low | $1.41 | $3.38 |
| Distance from 52-week high | -33.04% | -82.57% |
| Analyst consensus | none | buy |
| Avg. price target upside | +57.62% | +103.41% |
| Average volume | 2.02M | 4.17M |
| Shares outstanding | 165.24M | 147.78M |
| Employees | 100 | 3,595 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRWD has outperformed TLRY by 224.1 percentage points over the past year.
About Ironwood Pharmaceuticals
IRWD stock →Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Tilray Brands
TLRY stock →Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness.
Health Care · Medicinal Chemicals and Botanical Products · 3,595 employees
IRWD vs TLRY FAQ
Which is bigger, Ironwood Pharmaceuticals or Tilray Brands?
Ironwood Pharmaceuticals (IRWD) is larger, with a market capitalization of $639.48M compared with $520.19M for Tilray Brands (TLRY).
Which stock has performed better over the past year, IRWD or TLRY?
IRWD returned +144.94% over the past 12 months, compared with -79.13% for TLRY (price return, excluding dividends). Past performance does not predict future results.
Are Ironwood Pharmaceuticals and Tilray Brands in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Ironwood Pharmaceuticals and Medicinal Chemicals and Botanical Products for Tilray Brands.